Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR72_21 NK cells
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR72_21 NK cells is an investigational, allogeneic "off-the-shelf" cell therapy consisting of cord blood-derived natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) targeting CD72. The CAR construct is nanobody-based (VHH-derived) and incorporates a 4-1BB costimulatory domain. To enhance therapeutic efficacy and persistence in the immunosuppressive environment of B-cell malignancies, the cells are "armored" to co-express interleukin-21 (IL-21). Developed for the treatment of chronic lymphocytic leukemia (CLL) and Richter transformation (RT), CAR72_21 has demonstrated potent in vitro cytotoxicity against tumor cell lines and primary patient samples, showing potential synergy when combined with antibodies like obinutuzumab.
- Other names
- IL21-armored CD72-targeting nanobody-based CAR-NKIL-21-armored CD72-targeting nanobody-based CAR-NKIL 21-armored CD72-targeting nanobody-based CAR-NKanti-CD72 nanoCAR cord-blood NK productanti-CD-72 nanoCAR cord-blood NK productanti-CD 72 nanoCAR cord-blood NK product
02
Targets
CD (Cluster of Differentiation antigens)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on CAR72_21 NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR72_21 NK cells.